Research ExplorerPublicationsAutologous Stem Cell Transplantation in Multiple Myeloma in ...

Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis

Standard

Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis. / Thoennissen, Gabriela B; Görlich, Dennis; Bacher, Ulrike; Aufenberg, Thomas; Hüsken, Anne-Christin; Hansmeier, Anna Antonia; Evers, Georg; Mikesch, Jan-Henrik; Fritz, Fleur; Bokemeyer, Carsten; Müller-Tidow, Carsten; Stelljes, Matthias; Mesters, Rolf M; Krug, Utz; Kropff, Martin H; Thoennissen, Nils H; Berdel, Wolfgang E.

In: ACTA HAEMATOL-BASEL, Vol. 137, No. 3, 2017, p. 163-172.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Thoennissen, GB, Görlich, D, Bacher, U, Aufenberg, T, Hüsken, A-C, Hansmeier, AA, Evers, G, Mikesch, J-H, Fritz, F, Bokemeyer, C, Müller-Tidow, C, Stelljes, M, Mesters, RM, Krug, U, Kropff, MH, Thoennissen, NH & Berdel, WE 2017, 'Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis', ACTA HAEMATOL-BASEL, vol. 137, no. 3, pp. 163-172. https://doi.org/10.1159/000463534

APA

Thoennissen, G. B., Görlich, D., Bacher, U., Aufenberg, T., Hüsken, A-C., Hansmeier, A. A., Evers, G., Mikesch, J-H., Fritz, F., Bokemeyer, C., Müller-Tidow, C., Stelljes, M., Mesters, R. M., Krug, U., Kropff, M. H., Thoennissen, N. H., & Berdel, W. E. (2017). Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis. ACTA HAEMATOL-BASEL, 137(3), 163-172. https://doi.org/10.1159/000463534

Vancouver

Thoennissen GB, Görlich D, Bacher U, Aufenberg T, Hüsken A-C, Hansmeier AA et al. Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis. ACTA HAEMATOL-BASEL. 2017;137(3):163-172. https://doi.org/10.1159/000463534

Bibtex

@article{c2aa8a0fd7c94b418080d0d1edaa7865,
title = "Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis",
abstract = "Within this retrospective single-center study, we analyzed the survival of 320 multiple myeloma (MM) patients receiving melphalan high-dose chemotherapy (HDCT) and either single (n = 286) or tandem (n = 34) autologous stem cell transplantation (ASCT) from 1996 to 2012. Additionally, the impact of novel induction regimens was assessed. Median follow-up was 67 months, median overall survival (OS) 62 months, median progression-free survival (PFS) 33 months (95% CI 27-39), and treatment-related death (TRD) 3%. Multivariate analysis revealed age ≥60 years (p = 0.03) and stage 3 according to the International Staging System (p = 0.006) as adverse risk factors regarding PFS. Median OS was significantly better in newly diagnosed MM patients receiving induction therapy with novel agents, e.g., bortezomib, thalidomide, or lenalidomide, compared with a traditional regimen (69 vs. 58 months; p = 0.01). More patients achieved at least a very good partial remission in the period from 2005 to 2012 than from 1996 to 2004 (65 vs. 30%; p < 0.001), with a longer median OS in the later period (71 vs. 52 months, p = 0.027). In conclusion, our analysis confirms HDCT-ASCT as an effective therapeutic strategy in an unselected large myeloma patient cohort with a low TRD rate and improved prognosis due to novel induction strategies.",
keywords = "Adult, Aged, Antineoplastic Agents, Alkylating, Antineoplastic Protocols, Cohort Studies, Combined Modality Therapy, Disease-Free Survival, Female, Humans, Induction Chemotherapy, Male, Melphalan, Middle Aged, Multiple Myeloma, Prognosis, Retrospective Studies, Stem Cell Transplantation, Transplantation, Autologous, Journal Article",
author = "Thoennissen, {Gabriela B} and Dennis G{\"o}rlich and Ulrike Bacher and Thomas Aufenberg and Anne-Christin H{\"u}sken and Hansmeier, {Anna Antonia} and Georg Evers and Jan-Henrik Mikesch and Fleur Fritz and Carsten Bokemeyer and Carsten M{\"u}ller-Tidow and Matthias Stelljes and Mesters, {Rolf M} and Utz Krug and Kropff, {Martin H} and Thoennissen, {Nils H} and Berdel, {Wolfgang E}",
note = "{\textcopyright} 2017 S. Karger AG, Basel.",
year = "2017",
doi = "10.1159/000463534",
language = "English",
volume = "137",
pages = "163--172",
journal = "ACTA HAEMATOL-BASEL",
issn = "0001-5792",
publisher = "S. Karger AG",
number = "3",

}

RIS

TY - JOUR

T1 - Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis

AU - Thoennissen, Gabriela B

AU - Görlich, Dennis

AU - Bacher, Ulrike

AU - Aufenberg, Thomas

AU - Hüsken, Anne-Christin

AU - Hansmeier, Anna Antonia

AU - Evers, Georg

AU - Mikesch, Jan-Henrik

AU - Fritz, Fleur

AU - Bokemeyer, Carsten

AU - Müller-Tidow, Carsten

AU - Stelljes, Matthias

AU - Mesters, Rolf M

AU - Krug, Utz

AU - Kropff, Martin H

AU - Thoennissen, Nils H

AU - Berdel, Wolfgang E

N1 - © 2017 S. Karger AG, Basel.

PY - 2017

Y1 - 2017

N2 - Within this retrospective single-center study, we analyzed the survival of 320 multiple myeloma (MM) patients receiving melphalan high-dose chemotherapy (HDCT) and either single (n = 286) or tandem (n = 34) autologous stem cell transplantation (ASCT) from 1996 to 2012. Additionally, the impact of novel induction regimens was assessed. Median follow-up was 67 months, median overall survival (OS) 62 months, median progression-free survival (PFS) 33 months (95% CI 27-39), and treatment-related death (TRD) 3%. Multivariate analysis revealed age ≥60 years (p = 0.03) and stage 3 according to the International Staging System (p = 0.006) as adverse risk factors regarding PFS. Median OS was significantly better in newly diagnosed MM patients receiving induction therapy with novel agents, e.g., bortezomib, thalidomide, or lenalidomide, compared with a traditional regimen (69 vs. 58 months; p = 0.01). More patients achieved at least a very good partial remission in the period from 2005 to 2012 than from 1996 to 2004 (65 vs. 30%; p < 0.001), with a longer median OS in the later period (71 vs. 52 months, p = 0.027). In conclusion, our analysis confirms HDCT-ASCT as an effective therapeutic strategy in an unselected large myeloma patient cohort with a low TRD rate and improved prognosis due to novel induction strategies.

AB - Within this retrospective single-center study, we analyzed the survival of 320 multiple myeloma (MM) patients receiving melphalan high-dose chemotherapy (HDCT) and either single (n = 286) or tandem (n = 34) autologous stem cell transplantation (ASCT) from 1996 to 2012. Additionally, the impact of novel induction regimens was assessed. Median follow-up was 67 months, median overall survival (OS) 62 months, median progression-free survival (PFS) 33 months (95% CI 27-39), and treatment-related death (TRD) 3%. Multivariate analysis revealed age ≥60 years (p = 0.03) and stage 3 according to the International Staging System (p = 0.006) as adverse risk factors regarding PFS. Median OS was significantly better in newly diagnosed MM patients receiving induction therapy with novel agents, e.g., bortezomib, thalidomide, or lenalidomide, compared with a traditional regimen (69 vs. 58 months; p = 0.01). More patients achieved at least a very good partial remission in the period from 2005 to 2012 than from 1996 to 2004 (65 vs. 30%; p < 0.001), with a longer median OS in the later period (71 vs. 52 months, p = 0.027). In conclusion, our analysis confirms HDCT-ASCT as an effective therapeutic strategy in an unselected large myeloma patient cohort with a low TRD rate and improved prognosis due to novel induction strategies.

KW - Adult

KW - Aged

KW - Antineoplastic Agents, Alkylating

KW - Antineoplastic Protocols

KW - Cohort Studies

KW - Combined Modality Therapy

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Induction Chemotherapy

KW - Male

KW - Melphalan

KW - Middle Aged

KW - Multiple Myeloma

KW - Prognosis

KW - Retrospective Studies

KW - Stem Cell Transplantation

KW - Transplantation, Autologous

KW - Journal Article

U2 - 10.1159/000463534

DO - 10.1159/000463534

M3 - SCORING: Journal article

C2 - 28399522

VL - 137

SP - 163

EP - 172

JO - ACTA HAEMATOL-BASEL

JF - ACTA HAEMATOL-BASEL

SN - 0001-5792

IS - 3

ER -